Avid Bioservices Inc (CDMO)

[goodJohnhunting]

KT,

you are calling out how there can be more therapeutic value potential for anti-PS agents when working in tandem with substances like statins, that can make the "inside out" PS sites more accessible for Bavi family attachment, which in turn, can assist the bodies own anti-tumor immune response effectiveness. You are also suggesting that this sort of "helper" mechanism from other substances may show itself to be an essential part of the Bavi family PS or ES targeting agents aiding a therapeutic response

Yes, that's close enough. However, there would be more potential in viral strategies, such as HIV, Ebola etc..

For example, Ebola replication requires the cholesterol transporter protein NPC1. The intriguing idea is that NPCI demonstrates an affinity to bind with glycoproteins, and it's the process of cholesterol transport and GP binding that allow for viral entry, and replication. This has been substantiated in recent studies?. The obvious correlation and effect, in regards to therapy, would be a reduction in transporter proteins (Statin) and AntiPS (Bavi) initiating both immunomodulation, and reduced viral PS pathway vectors.

Something I didn't see you address yet (I am still scanning through a backlog of a large number of unread posts) is the biomarking/tumor labeling benefit prospects being examined as part of PPHM tech research. This biomarking for imaging and simple categorization of tumor types (I recall not all tumors are marked as well as others based on earlier posts by others) was discussed on this board as being a prospectively market valuable offshoot from Bavi research that could generate revenue for PPHM fairly short term (maybe only a year or two out). Do you see the tumor marking value as warranting further research pursuit, distinct from Bavi family/betabody therapeutic value research?

Yes, if you recall my OHPSLSAE Theory?

Oxidative Hydrolyzed PS Lysis Species Associated Exosomes.

I've theorized that, since PS is a bioactive lipid, a changing biologic effect within a tumor microenvironment could be measurable. This would be present as a result of tumor cell destruction by way of antiPS. Or, in other words a byproduct of an effective AntiPS therapy.

All the best,
John